Inovelon has been approved as an adjunctive therapy in Lennox-Gastaut Syndrome (LGS) from the Committee for Medicinal Products for Human Use, the scientific body of the European Medicines Evaluation Agency.
Inovelon has been shown to be effective in the treatment of seizures associated with LGS, a severe form of epilepsy that develops in early childhood. The positive opinion was in response to the marketing authorization application submitted by Eisai in March 2005 for an approval of Inovelon.
Inovelon was also granted orphan drug status by the European Commission in October, 2004.
Eisai is currently enhancing its neurology franchise, which includes Aricept for the treatment of Alzheimer's disease and the anti-epilepsy agent Zonegran.